<DOC>
	<DOCNO>NCT01616758</DOCNO>
	<brief_summary>The primary efficacy analysis clinical benefit 6 month measure modified Response Evaluation Criteria Solid Tumors RECIST classification . Key secondary endpoint objective response rate , progression free survival , time progression , duration response , effect physical function , effect tumor progression woman Androgen Receptor positive breast cancer also assess .</brief_summary>
	<brief_title>Phase II Study GTx024 Women With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Give voluntary , sign informed consent accordance institutional policy . 2 . Be woman diagnose ER positive metastatic breast cancer . 3 . Have metastatic breast cancer measurable lesion prior enrollment bone disease prior enrollment . A measurable lesion define one lesion whose long diameter ( LD ) accurately measure 10 mm CT MRI technique use 5 mm contiguous reconstruction algorithm . Measurable lesion must least 2 time slice thickness least two time size CT scan interval cut . Patients bone disease nonmeasurable lesion eligible . 4 . Be clinically confirm postmenopausal . Subjects must undergo onset spontaneous , medical surgical menopause prior start study . ( Spontaneous menopause define natural cessation ovarian function indicate amenorrheic least 12 month . If subject amenorrheic &gt; equal 6 month &lt; 12 month , must serum FSH concentration &gt; equal 50 mIU/mL estradiol concentration less equal 25 pg/mL . Medical menopause define treatment luteinizing hormone receptor hormone agonist surgical menopause define bilateral oophorectomy ) . 5 . Have treat respond previous adjuvant hormonal therapy 3 year previous hormonal therapy metastatic disease 6 month prior disease progression . 6 . Have radiation therapy breast cancer within 2 week randomization study plan radiation therapy participation study . 7 . Be willing provide formalinfixed , paraffinembedded block ( ) cancerous tissue biopsy metastatic tumor lesion ( ) collect two ( 2 ) year prior study entry component enrollment study determination AR ER status . Tissue sample biopsy primary tumor lesion also provide available . 8 . Serum creatinine 2.0 mg/dL 9 . Have ECOG score 2 . 10 . Be age 18 year . Exclusion Criteria Subjects follow NOT eligible enrollment study : 1 . Have triple negative breast cancer 2 . Have , judgment Investigator , clinically significant concurrent illness psychological , familial , sociological , geographical concomitant condition would permit adequate followup compliance study protocol 3 . Have uncontrolled hypertension ( systolic blood pressure great 150 mm Hg and/or diastolic blood pressure great 100 mm Hg despite treatment antihypertensive drug ) 4 . Untreated congestive heart failure untreated angina 5 . Have Stage 4 chronic obstructive pulmonary disease ( COPD ) 6 . Have positive screen Hepatitis B consist HBsAg ( Hepatitis B Surface Antigen ) , unless subject diagnose &gt; 10 year prior enrollment evidence active liver disease 7 . The presence consistently abnormal clinical laboratory test ( Appendix B ) value consider clinically significant . In addition , subject total bilirubin 2 time upper limit normal ( ULN ) liver enzyme ( ALT/SGOT AST/SGPT ) 1.5 time ULN without evidence liver metastases 5 time ULN subject evidence liver metastasis admit study 8 . Have positive screen hepatitis A antibody IgM HIV 9 . Have receive chemotherapy metastatic breast cancer within 3 month prior enrollment study expect receive chemotherapy metastatic breast cancer study 10 . Be currently take testosterone , methyltestosterone , oxandrolone ( Oxandrin® ) , oxymetholone , danazol , fluoxymesterone ( Halotestin® ) , testosteronelike agent ( dehydroepiandrosterone ( DHEA ) , androstenedione , androgenic compound , include herbal ) , antiandrogens . Previous therapy testosterone testosteronelike agent acceptable 30day washout ( previous testosterone therapy long term depot within past 6 month , site contact medical monitor ( 18776932723 ) study determine appropriate washout period ) . 11 . Have untreated uncontrolled brain metastasis 12 . Have diagnose treated cancer within previous two year , breast cancer nonmelanoma carcinoma skin .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>